Author:
Haïk S.,Brandel J. P.,Salomon D.,Sazdovitch V.,Delasnerie-Lauprêtre N.,Laplanche J. L.,Faucheux B. A.,Soubrié C.,Boher E.,Belorgey C.,Hauw J. J.,Alpérovitch A.
Abstract
Quinacrine has been reported as an antiprion agent and proposed as an immediately applicable treatment for Creutzfeldt–Jakob disease (CJD). The authors report the results of an open compassionate procedure to which 32 CJD patients had access. In some genotypic subgroups, a slight but nonsignificant increase in survival was observed, likely due to biased inclusion of long-term surviving patients. There was no pathologic evidence of a beneficial effect of quinacrine treatment.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Cited by
81 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献